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Abstract 
Background: A growing number of rapid Helicobacter pylori antibody tests are commercially available now, however, 
some of these tests are often used without sufficient evaluation. The aim of this study was to evaluate the perfor‑
mance of a commercially available rapid whole‑blood immunoassay (gabControl® H. pylori; gabmed GmbH, Köln, 
Germany), for the qualitative detection of IgG antibodies against H. pylori with the 13C‑urea breath test (13C‑UBT) serv‑
ing as a reference method.
Methods: A total of 108 consecutive outpatients, who were referred for 13C‑UBT by general practitioners and special‑
ists, were also tested for H. pylori infection by the gabControl® H. pylori immunoassay. The clinical performance of this 
rapid whole‑blood test was evaluated by determining the sensitivity, specificity, positive predictive value (PPV), and 
negative predictive value (NPV) compared to the 13C‑UBT. The agreement between the two tests was calculated using 
Cohen’s Kappa (κ) with 95 % confidence intervals (CI).
Results: The agreement between the gabControl® H. pylori assay and the 13C‑UBT was 0.62 [95 % confidence 
intervals (CIs) 0.47–0.76; P < 0.001]. With the 13C‑UBT serving as the non‑invasive gold standard method of H. pylori 
diagnosis, the gabControl® H. pylori assay demonstrated a sensitivity and specificity of 91.4 and 76.7 %, respectively, 
with a PPV of 65.3 % and a NPV of 94.9 %. Seventeen (15.7 %) individuals with a positive H. pylori anamnesis showed 
a negative 13C‑UBT and were typed positive by the gabControl® H. pylori assay. Of these, 13 (76.5 %) and 3 individuals 
(17.6 %) had completed one and two eradication therapies, respectively.
Conclusions: The gabControl® H. pylori immunoassay is a rapid and easy to use first line screening tool for H. pylori 
IgG antibody detection in daily clinical practice. However, this assay should not be used for confirmation of the suc‑
cessful H. pylori eradication after antibiotic treatment.
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Background
Helicobacter pylori infection is still a common condition 
worldwide. In North Europe and North America, about 
one-third of adults are infected, whereas in South-East 
Europe, South America, and in Asia, the H. pylori preva-
lence is reported to be higher than 50 % [1].
Since the H. pylori infection was recognized as a causa-
tive agent of chronic active gastritis and a risk factor for 
ulcer disease, gastric cancer and the mucosa-associated 
lymphoid tissue (MALT) lymphoma, numerous invasive 
and non-invasive methods for the accurate detection of 
this bacterium have been developed. Invasive techniques 
include biopsy-based histological methods, culture of the 
bacterium, the rapid urease test, and molecular tests (e.g. 
real-time PCR). Non-invasive methods encompass the 
13C-urea breath test (13C-UBT), the stool antigen test, 
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and the H. pylori antibody detection by serological tests 
[2–4].
The 13C-UBT is considered the non-invasive gold 
standard method of H. pylori diagnosis [5–7]. It is a 
simple and safe test, which is easily repeated and pro-
vides excellent accuracy for the initial diagnosis of H. 
pylori infection, as well as the confirmation of its eradi-
cation after treatment [7, 8]. In the presence of the H. 
pylori produced enzyme urease, the ingested labeled 
urea (13C-urea) is metabolized into labeled carbon diox-
ide (13CO2) and ammonia (NH3). The produced 13CO2 
diffuses into the blood vessels and is eliminated via the 
lungs. The expired air is collected in order to measure the 
activity of labeled carbon so as to detect individuals with 
H. pylori infection [5, 9, 10].
Since individuals infected with H. pylori develop a 
local and systematic immune response [11, 12], specific 
H. pylori antibodies can be detected by rapid serological 
assays. These tests are easy to perform, inexpensive, and 
enable immediate patient testing for H. pylori antibod-
ies in general practice surgeries [13]. A previous study, 
which evaluated a rapid whole-blood test, demonstrated, 
that there was no difference in diagnostic accuracy 
between capillary (fingerstick) and venous blood (veni-
puncture) collection [14]. A growing number of rapid 
H. pylori antibody tests are commercially available now, 
however, some of these tests are often used without suf-
ficient evaluation.
The aim of this study was to evaluate the performance 
of a commercially available rapid whole blood immu-
noassay (gabControl® H. pylori; gabmed GmbH, Köln, 
Germany), for the qualitative detection of IgG antibodies 




In total, 108 patients, who were consecutively referred 
for 13C-UBT by general practitioners and specialists to 
our outpatient clinic, were also tested for H. pylori infec-
tion by the gabControl® H. pylori immunoassay (gabmed 
GmbH, Köln, Germany). The study period was from 
January to December 2015. The inclusion criteria were 
a minimum age of >15  years, an overnight fasting state 
and a non-smoking period >12  h before the 13C-UBT. 
Patients with antibiotic-based therapy at least 4  weeks 
before and/or proton pump inhibitor (PPI) therapy at 
least 2 weeks before the 13C-UBT were excluded from the 
study. An anamnesis was carried out about the history 
of H. pylori infections, completed eradication therapies, 
and intake of medication. Written informed consent was 
provided from all the patients. The ethical approval for 
this study was obtained from the Ethical Committee of 
Upper Austria, Linz, Austria. The study was carried out 
in accordance with the latest version of the Declaration 
of Helsinki.
13C‑UBT
Isotope ratio mass spectrometry was employed using 
the IRIS®-13C-Infrared Isotope Analyzer System (Wag-
ner Analysen Technik GmbH, Bremen, Germany). The 
13C-UBT was performed according to the manufacturer’s 
instructions. Briefly: after a 12  h fasting period, breath 
samples were obtained before (baseline) and 30  min 
after the test drink intake (75 mg 13C-urea from the cap-
sule dissolved in 200  mL fruit juice) early in the morn-
ing (8:00–10.00 a. m.). 13C/12C-isotope ratio differences 
between the value at 30 min and the baseline value were 
determined and expressed in delta over baseline (DOB, 
‰). A sample was considered positive if the 30 min value 
was above a 4 ‰ cut-off level [15]. Eating, drinking and/
or smoking were not allowed until the 13C-UBT was 
completed.
GabControl® H. pylori
This commercially available test is a qualitative membrane 
based immunoassay for the qualitative detection of H. 
pylori IgG antibodies in whole-blood, serum or plasma. 
The test was performed in accordance with the manufac-
turer’s instructions. Approximately 50  µL of fingerstick 
whole-blood was sampled in a glass capillary tube and 
transferred to the specimen well (S) on the test device 
(Fig.  1a–c). One drop (approximately 40  µL) of dilution 
buffer containing H. pylori antigen-coated particles was 
added and allowed to migrate along a lateral-flow mem-
brane thereby interacting with anti-human IgG antibodies 
immobilized as parallel lines. The test results were read 
after 10  min: a red control (C) line signal together with 
a red test (T) line signal (intense or faint) indicated the 
presence of H. pylori IgG antibody (Fig. 1a, b); showing a 
single red C line signal only, the assay was interpreted as 
negative (Fig. 1c). Assay read-out was performed indepen-
dently by two physicians (i.e. four eyes principle), which 
were both blinded to the respective 13C-UBT result.
Statistical analysis
The agreement between the 13C-UBT and the gabCon-
trol® H. pylori assay was calculated using Cohen’s Kappa 
(κ) with 95 % confidence intervals (CIs) [16]. Sensitivity, 
specificity, positive predictive value (PPV) and negative 
predictive value (NPV) of the gabControl® H. pylori assay 
were calculated compared to the 13C-UBT. No adjust-
ment for type I error was made. Therefore the concerning 
P values are only descriptive. Analyse-it® software ver-
sion 2.30 (Analyse-it Software, Ltd, Leeds, United King-
dom) was used for statistical analysis.
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Results
Study population characteristics
Of 108 consecutively enrolled patients, 36 (33.3 %) were 
male and 72 (66.7  %) were female. The median age was 
44.0 (range: 15–88) years. The main demographic and 
clinical characteristics of the study population are pro-
vided in Table  1. Fifty-eight (53.7  %) individuals had a 
positive history of previous H. pylori infections.
Performance of the gabControl® H. pylori assay
The gabControl® H. pylori assay was found positive and 
negative in 49/108 (45.4 %) and 59/108 (54.6 %) patients, 
respectively (Table  2). Of those patients with a posi-
tive result, fifteen (30.6  %) individuals showed faint red 
colored changes in the test line region (T) only (Fig. 1b).
The agreement between the gabControl® H. pylori 
assay and the 13C-UBT was 0.62 (95  % CI 0.47–0.76; 
P  <  0.001). With the 13C-UBT serving as the non-inva-
sive gold standard method of H. pylori diagnosis [5–7], 
the gabControl® H. pylori assay demonstrated a sensitiv-
ity and specificity of 91.4 and 76.7 %, respectively, with a 
PPV of 65.3 % and a NPV of 94.9 % (Table 2).
Thirty-five (32.4  %) individuals had a positive 13C-
UBT. Twenty-seven (77.1 %) of these patients had a posi-
tive H. pylori anamnesis, whereas in 8 patients (22.9 %) 
H. pylori infection was detected for the first time. Sev-
enteen (15.7  %) individuals with a positive H. pylori 
anamnesis showed a negative 13C-UBT and were typed 
positive by the gabControl® H. pylori assay. Of these, 13 
(76.5  %) and 3 individuals (17.6  %) had completed one 
and two eradication therapies, respectively. One patient 
(5.9 %), however, did not undergo any kind of antibiotic 
treatment.
Discussion
This study aimed to compare the performance of the gab-
Control® H. pylori rapid immunoassay with the 13C-UBT 
in 108 patients, who were referred by general practition-
ers and specialists to our outpatient clinic. As the 13C-UBT 
Fig. 1 Typical reactivity patters obtained for the gabControl® H. pylori immunoassay: a thirty‑four (31.5 %) individuals showed an intense T line 
signal, b 15 (13.9 %) individuals were observed with faint to faintest T line signals, c 59 (54.6 %) patients demonstrated a C line signal only. C control 
line; T test line
Table 1 Basic characteristics of the study population
Study population
Patients n = 108
Gender
Male n = 36 (33.3 %)
Female n = 72 (66.7 %)
Median age (years) 44 (range: 15–88)
History of previous H. pylori infections
Negative history n = 50 (46.3 %)
Positive history n = 58 (53.7 %)
Completed eradication therapies (one or more) n = 54 (50 %)
Table 2 GabControl® H. pylori versus 13C-UBT
a  The gabControl® H. pylori immunoassay showed a sensitivity of 91.4 % and a 
specificity of 76.7 % with the 13C-UBT serving as a reference method
n = 108
GabControl® H. pylori a +  GabControl® H. pyloria − 
13C‑UBT + 32 (29.6 %) 3 (2.8 %)
13C‑UBT − 17 (15.7 %) 56 (51.9 %)
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was considered the non-invasive gold standard method of 
H. pylori diagnosis [5–7], the gabControl® H. pylori assay 
demonstrated a sensitivity and specificity of 91.4 and 76.7 %, 
respectively, with a PPV of 65.3 % and a NPV of 94.9 %.
Several previous studies have evaluated other rapid 
whole blood test kits for H. pylori antibody detection, 
reporting sensitivities and specificities of 80.3–89.5  % 
and 78.0–93.5 %, and PPVs and NPVs of 83–92.9 % and 
57.4–93.5 %, respectively [13, 17–19].
Herein, seventeen patients (15.7 %), who had a negative 
13C-UBT result were found positive for H. pylori antibody 
by the gabControl® H. pylori testing. Of these, 16 (94.1 %) 
individuals had a positive H. pylori anamnesis with one 
or two completed eradication therapies most likely 
responsible for the relatively low specificity of 76.7  % 
observed for the gabControl® H. pylori assay as well as 
the substantial agreement of 0.62 (95  % CI 0.47–0.76; 
P  <  0.001) between the two methodologies investigated 
here. Patients with previous eradication therapy might 
recently have overcome their infection and the 13C-UBT, 
as an indicator of current active infection, might be nega-
tive [20, 21]. Furthermore, it is known that it may take 
more than 1 year for H. pylori antibody to disappear after 
successful eradication [22]. Moreover, post-treatment 
circulating H. pylori antibodies are considered to remain 
positive for a significant period or perhaps indefinitely in 
some patients [3, 4, 20].
The intake of proton pump inhibitors (PPIs) may be 
another possible explanation of discrepant test results 
between the 13C-UBT and the gabControl® H. pylori assay. 
While PPI intake at least 2 weeks before the 13C-UBT was 
an exclusion criterion of this study, the authors cannot guar-
antee, that all individuals strictly followed this instruction. 
Individuals with PPI intake within 2 weeks before the 13C-
UBT may have false-negative breath test results, whereas H. 
pylori antibodies are serologically detectable [23–25].
Previous studies, which were performed in various 
populations with different geographical and socio-eco-
nomic status, demonstrated, that the prevalence of anti-
bodies against H. pylori increases with age [26–28]. A 
cross-sectional population study in Germany comprising 
1797 individuals showed a H. pylori antibody prevalence 
of 48  % [29]. These seroprevalence data are in agree-
ment with our study that found IgG antibodies against H. 
pylori in 49/108 (45.4 %) individuals.
In clinical practice, it should be considered, that a posi-
tive IgG serology does not necessarily indicate an ongo-
ing infection [30]. As a consequence the 13C-UBT may 
not be replaced through rapid whole-blood IgG anti-
body screening tests for confirmation of the successful H. 
pylori eradication after antibiotic treatment.
Using finger-stick blood samples the gabControl® H. 
pylori assay is rapid and easy to perform as centrifugation 
is no necessary and results are available within 10  min. 
However, low antibody titers resulting in faintest signal 
intensities may lead to false negative read-outs as inter-
pretation becomes highly subjective and should therefore 
be based on the four eyes principle.
The major limitation of this study is the lack of invasive 
biopsy-based methods (e.g. histology, bacterial culture 
and real-time PCR) for H. pylori detection.
In conclusion, the gabControl® H. pylori immunoassay 
is a rapid and easy to use first-line screening tool for H. 
pylori IgG antibody detection in daily clinical practice. 
However, it should not be used for confirmation of the 
successful H. pylori eradication after antibiotic treatment.
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